Release Date: March 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: How does the 9.6% growth in P&C renewals reconcile with the 4-6% guidance? A: Francois de Varenne, Deputy CEO and CFO, explained that the 9.6% growth reflects the success of the January 1 renewals, but the company maintains its 4-6% guidance due to factors like the lag effect in translating gross premium to insurance revenue and the impact of large commutations. Jean-Paul Conoscente, CEO of SCOR P&C, added that the growth in the Alternative Solutions portfolio affects the ISR and IFRS 17 figures.
Q: Can you clarify the impact of one-offs on net income and future buffer building? A: Francois de Varenne stated that the Q4 results include minimal one-offs, with a strong underlying performance in P&C and Life & Health. The effective tax rate was lower due to strategic profit repatriation. The company has already exceeded its buffer-building target significantly and will only pursue further buffer building opportunistically.
Q: What is the status of the P&C reserving buffer and future plans? A: Francois de Varenne confirmed that SCOR has surpassed its EUR300 million buffer target well ahead of schedule. The company will now adopt an opportunistic approach to buffer building, depending on profitability, but has no specific targets beyond the current achievement.
Q: What are the expectations for Life & Health experience variances in 2025? A: Francois de Varenne noted that while there was a negative experience variance in the US in Q4, the company is comfortable with its updated assumptions. The guidance for the insurance service result in 2025 accounts for some volatility, but significant improvements are expected as management actions continue.
Q: What are the key risks to maintaining stable technical margins in 1/1 renewals? A: Jean-Paul Conoscente highlighted that the main risk is how prices hold for upcoming renewals. The California wildfires and early consumption of cat budgets may stabilize prices, but the company remains cautious about managing its cat budget.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。